We are live on ! Find out more
PPBT

Purple Biotech
PPBT

14 hedge funds and large institutions have $378K invested in Purple Biotech in 2024 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 2

40% more funds holding

Funds holding: 10 → 14 (+4)

0% less ownership

Funds ownership: 0% → 0% (-0%)

0% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 2

60% less capital invested

Capital invested by funds: $946K → $378K (-$568K)

79% less call options, than puts

Call options by funds: $35K | Put options by funds: $167K

Holders
14
Holders Change
+4
Holders Change %
+40%
% of All Funds
0.18%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
2
Reduced
2
Closed
2
Calls
$35K
Puts
$167K
Net Calls
-$132K
Net Calls Change
-$132K

Top Buyers

Rank Fund Capital Flow
1
KWA
Kingswood Wealth Advisors
California
+$129K
2
TSS
Two Sigma Securities
New York
+$59.2K
3
UBS Group
UBS Group
Switzerland
+$41.5K
4
Group One Trading
Group One Trading
Illinois
+$32.9K
5
BNP Paribas Financial Markets
BNP Paribas Financial Markets
France
+$6.54K

Top Sellers

Rank Fund Capital Flow
1
AC
Armistice Capital
New York
-$877K
2
Morgan Stanley
Morgan Stanley
New York
-$11.3K
3
JP Morgan Chase
JP Morgan Chase
New York
-$234
4
TRCT
Tower Research Capital (TRC)
New York
-$77
5
DB
Danske Bank
Denmark
-$22
Name Holding Trade Value Shares
Change 		Change in
Stake
KWA
1
Kingswood Wealth Advisors
California
$158K +$129K +3,359 New
TSS
2
Two Sigma Securities
New York
$72.1K +$59.2K +1,537 New
UBS Group
3
UBS Group
Switzerland
$50.6K +$41.5K +1,078 New
Group One Trading
4
Group One Trading
Illinois
$40.2K +$32.9K +855 +42,750%
BNP Paribas Financial Markets
5
BNP Paribas Financial Markets
France
$25.2K +$6.54K +170 +46%
Morgan Stanley
6
Morgan Stanley
New York
$24K -$11.3K -294 -36%
RhumbLine Advisers
7
RhumbLine Advisers
Massachusetts
$2.84K +$2.35K +61 New
CWM
8
Crowley Wealth Management
Delaware
$1.41K +$1.16K +30 New
TRCT
9
Tower Research Capital (TRC)
New York
$1.06K -$77 -2 -8%
Royal Bank of Canada
10
Royal Bank of Canada
Ontario, Canada
$1K – – –
TWC
11
TD Waterhouse Canada
Ontario, Canada
$938 – – –
SS
12
SBI Securities
Japan
$891 +$731 +19 New
GRP
13
Global Retirement Partners
California
$75 – – –
NSIM
14
North Star Investment Management
Illinois
$70 – – –
AC
15
Armistice Capital
New York
– -$877K -15,800 Closed
JP Morgan Chase
16
JP Morgan Chase
New York
– -$234 -4 Closed
DB
17
Danske Bank
Denmark
– -$22 – –

PPBT Hedge Fund Activity: Q4 2024 in Review

14 of the 7,593 institutional investors tracked by Wall St. Rank reported a position in Purple Biotech (PPBT) for Q4 2024, worth a combined $378K — down 60% from $946K a quarter earlier.

Buyers outnumbered sellers: 6 funds opened new PPBT positions and 2 closed out — a net gain of 4 holders — while 2 added to existing stakes and 2 trimmed.

The largest buyer was Kingswood Wealth Advisors, opening a new position worth an estimated $129K. The largest seller was Armistice Capital, exiting entirely with an estimated $877K sold.

  • 14 institutional investors held Purple Biotech (PPBT) as of Q4 2024, up from 10 in Q3 2024.
  • Funds reported $378K of Purple Biotech stock for Q4 2024, down 60% quarter-over-quarter.
  • 6 funds opened new Purple Biotech positions in Q4 2024 and 2 closed out, a net change of +4 holders.
  • The largest Purple Biotech buyer in Q4 2024 was Kingswood Wealth Advisors, an estimated $129K added.
  • The largest Purple Biotech seller in Q4 2024 was Armistice Capital, an estimated $877K sold.

Based on aggregated 13F filings for Q4 2024.